WO2004036215A3 - Diagnostic markers for therapeutic treatment - Google Patents

Diagnostic markers for therapeutic treatment Download PDF

Info

Publication number
WO2004036215A3
WO2004036215A3 PCT/IL2003/000857 IL0300857W WO2004036215A3 WO 2004036215 A3 WO2004036215 A3 WO 2004036215A3 IL 0300857 W IL0300857 W IL 0300857W WO 2004036215 A3 WO2004036215 A3 WO 2004036215A3
Authority
WO
WIPO (PCT)
Prior art keywords
level
parameter
treatment
disease state
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2003/000857
Other languages
French (fr)
Other versions
WO2004036215A9 (en
WO2004036215A2 (en
Inventor
Pnina Fishman
Lea Madi
Yehuda Sara Bar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to EP03758622A priority Critical patent/EP1554574A2/en
Priority to AU2003274649A priority patent/AU2003274649A1/en
Priority to JP2004544676A priority patent/JP2006503564A/en
Publication of WO2004036215A2 publication Critical patent/WO2004036215A2/en
Publication of WO2004036215A9 publication Critical patent/WO2004036215A9/en
Publication of WO2004036215A3 publication Critical patent/WO2004036215A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method for monitoring the effectiveness of an administered agent that interacts with the A3 adenosine receptor (A3AR) in treatment of a disease state in an individual is provided. The level of at least one parameter of a biological marker is determined and compared to a control level, the control level being the level of the parameter without treatment, which is determined either as the level of the parameter in the individual prior to treatment or the level of the parameter in untreated control subject having the disease state. Monitoring a change in these parameters versus control, may also be used for screening agents that interact with the A3AR for such that can be used for a treating a disease state.
PCT/IL2003/000857 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment Ceased WO2004036215A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03758622A EP1554574A2 (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment
AU2003274649A AU2003274649A1 (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment
JP2004544676A JP2006503564A (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41959502P 2002-10-21 2002-10-21
US60/419,595 2002-10-21

Publications (3)

Publication Number Publication Date
WO2004036215A2 WO2004036215A2 (en) 2004-04-29
WO2004036215A9 WO2004036215A9 (en) 2004-08-05
WO2004036215A3 true WO2004036215A3 (en) 2004-09-10

Family

ID=32108110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000857 Ceased WO2004036215A2 (en) 2002-10-21 2003-10-21 Diagnostic markers for therapeutic treatment

Country Status (4)

Country Link
EP (1) EP1554574A2 (en)
JP (1) JP2006503564A (en)
AU (1) AU2003274649A1 (en)
WO (1) WO2004036215A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113828A1 (en) * 2004-05-14 2005-12-01 King Pharmaceuticals Research & Development, Inc. Methods of diagnosing and prognosticating solid tumors and melanoma
AU2005310874B2 (en) 2004-12-02 2008-11-27 Can-Fite Biopharma Ltd. Treatment of inflammation
TWI443337B (en) * 2008-10-10 2014-07-01 Ct Hospitalier Universitaire Sainte Justine Methods for the classification and diagnosis of scoliosis
JP5689061B2 (en) * 2009-09-01 2015-03-25 タカラバイオ株式会社 Composition for reverse transcription polymerase chain reaction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAHARAV E ET AL: "THE EFFECT OF ADENOSINE AND THE A3 ADENOSINE RECEPTOR AGONIST IB-MECA ON JOINT INFLAMMATION AND AUTOIMMUNE DISEASES MODELS", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 10, no. SUPPL 1, 10 October 2002 (2002-10-10), pages S104, XP009026428, ISSN: 1107-3756 *
BAR-YEHUDA SARA ET AL: "Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: A new class of myeloprotective agents", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 10, no. Supplement 1, 10 October 2002 (2002-10-10), & 7TH WORLD CONGRESS ON ADVANCES IN ONCOLOGY AND THE 5TH INTERNATIONAL SYMPOSIUM ON MOLECULAR MEDICINE; HERSONISSOS, CRETE, GREECE; OCTOBER 10-12, 2002, pages S100, XP008031645, ISSN: 1107-3756 *
FISHMAN P ET AL: "ADENOSINE ACTS AS A CHEMOPROTECTIVE AGENT BY STIMULATING G-CSF PRODUCTION: A ROLE FOR A1 AND A3 ADENOSINE RECEPTORS", JOURNAL OF CELLULAR PHYSIOLOGY, LISS, NEW YORK, NY, US, vol. 183, no. 3, June 2000 (2000-06-01), pages 393 - 398, XP001003004, ISSN: 0021-9541 *
FISHMAN PNINA ET AL: "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.", ONCOGENE. 6 JUN 2002, vol. 21, no. 25, 6 June 2002 (2002-06-06), pages 4060 - 4064, XP002284081, ISSN: 0950-9232 *
FISHMAN PNINA ET AL: "The A3 adenosine receptor: A new target for cancer therapy and chemoprotection", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 6, no. Supplement 1, 2000, & JOINT MEETING OF THE 5TH WORLD CONGRESS ON ADVANCES IN ONCOLOGY AND THE 3RD INTERNATIONAL SYMPOSIUM; CRETE, GREECE; OCTOBER 19-21, 2000, pages S60, XP009024523, ISSN: 1107-3756 *
HASKÓ G ET AL: "Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 1996, vol. 157, no. 10, 15 November 1996 (1996-11-15), pages 4634 - 4640, XP002284385, ISSN: 0022-1767 *
MADI L ET AL: "HIGH EXPRESSION OF A3ARS IN MELANOMA AND COLON CARCINOMA CEL LINES: A TARGET FOR TUMOR CELL GROWTH INHIBITION", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, no. 4, August 2002 (2002-08-01), pages 560, XP002284082, ISSN: 0272-4391 *

Also Published As

Publication number Publication date
JP2006503564A (en) 2006-02-02
WO2004036215A9 (en) 2004-08-05
EP1554574A2 (en) 2005-07-20
AU2003274649A8 (en) 2004-05-04
WO2004036215A2 (en) 2004-04-29
AU2003274649A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
EP1698373B8 (en) Systems and methods for intra-operative stimulation
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2006041664A3 (en) Baroreflex activation and cardiac resynchronization for heart failure treatment
BR0016652A (en) Methods to inhibit cerebral amyloid angiopathy, to treat a disease state characterized by cerebral amyloid angiopathy in an individual, and to diagnose cerebral amyloid angiopathy in an individual
WO2008150490A3 (en) Uses and compositions for treatment of psoriasis and crohn's disease
WO2003034995A3 (en) Integrin targeting compounds
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
CY1107640T1 (en) METHOD FOR CERTIFICATING FACTORS FOR DIABETES TREATMENT
WO2007061554A3 (en) Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2006073671A8 (en) Protein activity modification
WO2001002050A3 (en) Method and system for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response
WO2002093173A3 (en) Screening method using pim1-kinase or pim3-kinase
BR9906926A (en) Compositions and methods for treating cells having double minute dna
WO2002092016A3 (en) Therapeutic use of rank antagonists
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2003011215A3 (en) Method and system to determine revised dosage
EP1162457A3 (en) Multiple coagulation test system and method of using a multiple coagulation test system
CA2069611A1 (en) Method to Detect Bone and Other Connective Tissue Disorders in Humans and Animals
WO2006029142A3 (en) Methods and systems for treating asthma and other respiratory diseases
Moss Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction< or= 30% should receive an implantable cardioverter-defibrillator
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2004016751A3 (en) Methods of treating neurodegenerative diseases
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
WO2003028536A3 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 13, 14, 24 AND 28, DESCRIPTION, REPLACED BY NEW PAGES 13, 14, 24 AND 28; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 2004544676

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003758622

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003758622

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003758622

Country of ref document: EP